Korea University Research and Business Foundation

Je Sang Ko

Jeong-Han Kim

Min-Soo Kang

The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.

CD133 related to anticancer agent resistance in colon cancer and use thereof

The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR&#x3b3;2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.

Use of human small leucine zipper protein in osteogenesis procedure

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR&#x3b3;2 to induce the formation of a complex of HDAC3 and PPAR&#x3b3;2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR&#x3b3;2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.

Growing community of inventors

Seoul, South Korea

Je Sang Ko